Zelboraf (vemurafenib) - Roche
Mekinist (trametinib) - Novartis, BeOne Medicines
Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients (clinicaltrials.gov) - Oct 8, 2026 - P2 | N=12 | Active, not recruiting | Sponsor: Anna Raciborska | Recruiting ➔ Active, not recruiting 
Enrollment closed • BRAF
http://clinicaltrials.gov/ct2/show/NCT04943224
 
Oct 8, 2026
 
Prev Next